Retatrutide Peptide – Premium Research Grade
Triple Agonist (GLP-1, GIP, Glucagon) | High Purity | Lab-Tested
Product Overview
Retatrutide is an advanced synthetic peptide designed as a triple receptor agonist,
targeting GLP-1, GIP, and glucagon pathways. This multi-receptor activity makes it a
highly valuable compound for next-generation metabolic and endocrine research.
Its engineered structure enhances receptor binding and biological activity, offering
researchers a powerful tool for studying complex metabolic interactions.
Key Features
- ✔ Triple agonist: GLP-1, GIP & glucagon receptors
- ✔ Extended biological activity
- ✔ ≥99% purity (HPLC tested)
- ✔ Lyophilized powder for enhanced stability
- ✔ High consistency manufacturing
- ✔ Research-grade quality
Mechanism of Action
Retatrutide simultaneously activates three key metabolic receptors,
enabling researchers to explore synergistic effects across multiple pathways.
- GLP-1: Supports glucose regulation and insulin signaling
- GIP: Influences lipid metabolism
- Glucagon: Plays a role in energy expenditure
Research Applications
- Advanced metabolic pathway studies
- Energy balance and expenditure research
- Insulin sensitivity investigations
- Endocrine system research
- Multi-receptor interaction analysis
⚡ High Demand – Limited Stock Available
Product Specifications
| Form: | Lyophilized Powder |
| Purity: | ≥99% |
| Structure: | Triple agonist peptide analog |
| Stability: | Enhanced via structural modifications |
Storage & Handling
- Store in a cool, dry place
- Protect from light
- Keep sealed until use
Why Choose Us?
- ✔ Premium research-grade quality
- ✔ Consistent batch testing
- ✔ Fast and secure shipping
- ✔ Trusted peptide supplier
Order Retatrutide Today
Upgrade your research with high-quality Retatrutide peptide.
⚠ Limited availability due to high demand.
Important Disclaimer
This product is intended for research use only. Not for human or veterinary consumption.
research peptides retatrutide, metabolic research peptide
Reviews
There are no reviews yet.